prof. dr. M.J.E. (Marian) Mourits

Professor Gynecological Oncology

E-mail:
m.j.e.mourits umcg.nl

Research

  1. 2020
  2. GEMO Study Collaborators, EMBRACE Collaborators, kConFab Investigators, HEBON Investigators, & ABCTB Investigators (2020). Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 52(1). https://doi.org/10.1038/s41588-019-0537-1
  3. 2019
  4. HEBON Grp, de Jonge, M. M., Ritterhouse, L. L., de Kroon, C. D., Vreeswijk, M. P. G., Segal, J. P., & Puranik, R. (2019). Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clinical Cancer Research, 25(24), 7517-7526. https://doi.org/10.1158/1078-0432.CCR-19-0848
  5. Mourits, M. J. E., Eggink, F., Jalving, M., de Bruyn, M., Bart, J., & Nijman, H. (2019). Ovarian cancer. In Textbook of Obstetrics and Gynaecology: a life course approach Bohn, Stafleu, Van Loghum.
  6. 2018
  7. Harmsen, M. G., Piek, J. M. J., Bulten, J., Casey, M. J., Rebbeck, T. R., Mourits, M. J., ... de Hullu, J. A. (2018). Peritoneal Carcinomatosis After Risk-Reducing Surgery in BRCA1/2 Mutation Carriers. Cancer, 124(5), 952-959. https://doi.org/10.1002/cncr.31211
  8. 2017
  9. Rozenberg, S., Maas, A., Mourits, M. J., Antoine, C., & Rees, M. (2017). Health and wellbeing after cancer. Maturitas, 105, 1-3. https://doi.org/10.1016/j.maturitas.2017.08.012
  10. Vermeulen, R. F. M., van Beurden, M., Kieffer, J. M., Bleiker, E. M. A., Valdimarsdottir, H. B., Massuger, L. F. A. G., ... Aaronson, N. K. (2017). Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. European Journal of Cancer, 84, 159-167. https://doi.org/10.1016/j.ejca.2017.07.018
  11. 2016
  12. Zaaijer, L. H., van Doorn, H. C., Mourits, M. J. E., van Beurden, M., de Hullu, J. A., Adank, M. A., ... Kriege, M. (2016). Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. British Jounal of Cancer, 115(10), 1174-1178. https://doi.org/10.1038/bjc.2016.333
  13. Vos, J. R., Oosterwijk, J. C., Aalfs, C. M., Rookus, M. A., Adank, M. A., van der Hout, A. H., ... Hereditary Breast Ovarian Canc Res (2016). Bias explains most of the parent-of-origin effect on breast cancer risk in BRCA1/2 mutation carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 25(8), 1251-1258. https://doi.org/10.1158/1055-9965.EPI-16-0182
  14. Droog, M., Nevedomskaya, E., Kim, Y., Severson, T., Flach, K. D., Opdam, M., ... Zwart, W. (2016). Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ER alpha in Tamoxifen-Associated Endometrial Carcinomas. Cancer Research, 76(13), 3773-3784. https://doi.org/10.1158/0008-5472.CAN-14-1813
  15. 2015
  16. Heemskerk-Gerritsen, B. A. M., Seynaeve, C., van Asperen, C. J., Ausems, M. G. E. M., Collee, J. M., van Doorn, H. C., ... Hereditary Breast Ovarian Canc Res (2015). Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. Jnci-Journal of the national cancer institute, 107(5), [033]. https://doi.org/10.1093/jnci/djv033
  17. 2014
Previous 1 2 3 4 Next

ID: 113226